Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2019

Open Access 01-12-2019 | Lung Cancer | Review

CD146 T cells in lung cancer: its function, detection, and clinical implications as a biomarker and therapeutic target

Authors: Ayobami Matthew Olajuyin, Adefunke Kafayat Olajuyin, Ziqi Wang, Xingru Zhao, Xiaoju Zhang

Published in: Cancer Cell International | Issue 1/2019

Login to get access

Abstract

CD146 alternatively called melanoma cell adhesion molecule (MCAM), is a biomarker and therapeutic target of clinical significance. It is found on different cells including the endothelial cells and lymphocytes which participate in heterotypic and homotypic ligand-receptor. This review concentrated on the CD146 expression T cells (or lymphocytes) centering on Treg in lung cancer. Here, we have also considered the vigorous investigation of CD146 mainly acknowledged new roles, essential mechanisms and clinical implications of CD146 in cancer. CD146 has progressively become a significant molecule, particularly recognized as a novel biomarker, prognosis and therapy for cancer. Hence, targeting CD146 expression by utilization of methanol extracts of Calotropis procera leaf may be useful for the treatment of carcinogenesis.
Literature
1.
Lehmann JM, Holzmann B, Breitbart EW, Schmiegelow P, Riethmüller G, Johnson JP. Discrimination between benign and malignant cells of melanocytic lineage by two novel antigens, a glycoprotein with a molecular weight of 113,000 and a protein with a molecular weight of 76,000. Cancer Res. 1987;47(3):841–5.PubMed
2.
Trzpis M, McLaughlin PM, de Leij LM, Harmsen MC. Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule. Am J Pathol. 2007;171(2):386–95.PubMedPubMedCentralCrossRef
3.
Wang Z, Yan X. CD146, a multi-functional molecule beyond adhesion. Cancer Lett. 2013;330(2):150–62.PubMedCrossRef
4.
Kratzer A, Chu HW, Salys J, Moumen Z, Leberl M, Bowler R, et al. Endothelial cell adhesion molecule CD146: implications for its role in the pathogenesis of COPD. J Pathol. 2013;230(4):388–98.PubMedCrossRef
5.
Uematsu K, Kawase T, Nagata M, Suzuki K, Okuda K, Yoshie H, et al. Tissue culture of human alveolar periosteal sheets using a stem-cell culture medium (MesenPRO-RS™): in vitro expansion of CD146-positive cells and concomitant upregulation of osteogenic potential in vivo. Stem cell Res. 2013;10(1):1–19.PubMedCrossRef
6.
Elshal MF, Khan SS, Takahashi Y, Solomon MA, McCoy JP. CD146 (Mel-CAM), an adhesion marker of endothelial cells, is a novel marker of lymphocyte subset activation in normal peripheral blood. Blood. 2005;106(8):2923–4.PubMedCrossRef
7.
Khan SS, Solomon MA, McCoy JP Jr. Detection of circulating endothelial cells and endothelial progenitor cells by flow cytometry. Cytom Part B. 2005;64(1):1–8.
8.
Stalin J, Nollet M, Dignat-George F, Bardin N, Blot-Chabaud M. Therapeutic and diagnostic antibodies to CD146: thirty years of research on its potential for detection and treatment of tumors. Antibodies. 2017;6(4):17.PubMedCentralCrossRef
9.
Espagnolle N, Guilloton F, Deschaseaux F, Gadelorge M, Sensébé L, Bourin P. CD 146 expression on mesenchymal stem cells is associated with their vascular smooth muscle commitment. J Cell Mol Med. 2014;18(1):104–14.PubMedCrossRef
10.
Bardin N, George F, Mutin M, Brisson C, Horschowski N, Frances V, et al. S-Endo 1, a pan-endothelial monoclonal antibody recognizing a novel human endothelial antigen. Tissue Antigens. 1996;48(5):531–9.PubMedCrossRef
11.
Bardin N, Moal V, Anfosso F, Daniel L, Brunet P, Sampol J, et al. Soluble CD146, a novel endothelial marker, is increased in physiopathological settings linked to endothelial junctional alteration. Thromb Haemost. 2003;90(11):915–20.PubMedCrossRef
12.
Kristiansen G, Yu Y, Schlüns K, Sers C, Dietel M, Petersen I. Expression of the cell adhesion molecule CD146/MCAM in non-small cell lung cancer. Anal Cell Pathol. 2003;25(2):77–81.PubMedPubMedCentralCrossRef
13.
Ilie M, Long E, Hofman V, Selva E, Bonnetaud C, Boyer J, et al. Clinical value of circulating endothelial cells and of soluble CD146 levels in patients undergoing surgery for non-small cell lung cancer. Br J Cancer. 2014;110(5):1236.PubMedPubMedCentralCrossRef
14.
Stalin J, Nollet M, Garigue P, Fernandez S, Vivancos L, Essaadi A, et al. Targeting soluble CD146 with a neutralizing antibody inhibits vascularization, growth and survival of CD146-positive tumors. Oncogene. 2016;35(42):5489.PubMedCrossRef
15.
England CG, Jiang D, Hernandez R, Sun H, Valdovinos HF, Ehlerding EB, et al. ImmunoPET imaging of CD146 in murine models of intrapulmonary metastasis of non-small cell lung cancer. Mol Pharm. 2017;14(10):3239–47.PubMedPubMedCentralCrossRef
16.
Arrieta O, Guzmán-de EA, Alba-Lopez L, Acosta-Espinoza A, Alatorre-Alexander J, Alexander-Meza J, et al. National consensus of diagnosis and treatment of non-small cell lung cancer. Rev Invest Clin. 2013;65:S5–84.PubMed
17.
Fitzmaurice C, Akinyemiju TF, Al Lami FH, Alam T, Alizadeh-Navaei R, Allen C, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study. JAMA Oncol. 2018;4(11):1553–68.PubMedCrossRef
18.
Arrieta O, Cardona AF, Corrales L, Campos-Parra AD, Sánchez-Reyes R, Amieva-Rivera E, et al. The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer. Lung Cancer. 2015;87(2):169–75.PubMedCrossRef
19.
Elshal MF, Khan SS, Raghavachari N, Takahashi Y, Barb J, Bailey JJ, et al. A unique population of effector memory lymphocytes identified by CD146 having a distinct immunophenotypic and genomic profile. BMC immunol. 2007;8(1):29.PubMedPubMedCentralCrossRef
20.
Guezguez B, Vigneron P, Lamerant N, Kieda C, Jaffredo T, Dunon D. Dual role of melanoma cell adhesion molecule (MCAM)/CD146 in lymphocyte endothelium interaction: MCAM/CD146 promotes rolling via microvilli induction in lymphocyte and is an endothelial adhesion receptor. J Immunol. 2007;179(10):6673–85.PubMedCrossRef
21.
Dagur PK, Biancotto A, Wei L, Sen HN, Yao M, Strober W, et al. MCAM-expressing CD4+ T cells in peripheral blood secrete IL-17A and are significantly elevated in inflammatory autoimmune diseases. J Autoimmun. 2011;37(4):319–27.PubMedPubMedCentralCrossRef
22.
Dagur PK, Biancotto A, Stansky E, Sen HN, Nussenblatt RB, McCoy JP. Secretion of interleukin-17 by CD8+ T cells expressing CD146 (MCAM). Clin immunol. 2014;152(1–2):36–47.PubMedPubMedCentralCrossRef
23.
Dagur PK, McCoy JP Jr. Endothelial-binding, proinflammatory T cells identified by MCAM (CD146) expression: characterization and role in human autoimmune diseases. Autoimmun Rev. 2015;14(5):415–22.PubMedPubMedCentralCrossRef
24.
Hassan LM, Galal TM, Farahat EA, El-Midany MM. The biology of Calotropis procera (Aiton) WT. Trees. 2015;29(2):311–20.CrossRef
25.
Sharma R, Thakur GS, Sanodiya BS, Savita A, Pandey M, Sharma A, et al. Therapeutic potential of Calotropis procera: a giant milkweed. ISOR J Pharm Bio Sci. 2012;4(2):42–57.
26.
Pandey A, Swarnkar V, Pandey T, Srivastava P, Kanojiya S, Mishra DK, et al. Transcriptome and metabolite analysis reveal candidate genes of the cardiac glycoside biosynthetic pathway from Calotropis procera. Sci Rep. 2016;6:34464.PubMedPubMedCentralCrossRef
27.
Mascolo N, Sharma R, Jain S, Capasso F. Ethnopharmacology of Calotropis procera flowers. J Ethnopharmacol. 1988;22(2):211–21.PubMedCrossRef
28.
Juncker T, Cerella C, Teiten M-H, Morceau F, Schumacher M, Ghelfi J, et al. UNBS1450, a steroid cardiac glycoside inducing apoptotic cell death in human leukemia cells. Biochem Pharmacol. 2011;81(1):13–23.PubMedCrossRef
29.
Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science. 1998;281(5381):1305–8.PubMedCrossRef
30.
31.
Russell JH, White CL, Loh DY, Meleedy-Rey P. Receptor-stimulated death pathway is opened by antigen in mature T cells. Proc Natl Acad Sci. 1991;88(6):2151.PubMedCrossRefPubMedCentral
32.
Wesselborg S, Janssen O, Kabelitz D. Induction of activation-driven death (apoptosis) in activated but not resting peripheral blood T cells. J Immunol. 1993;150(10):4338–45.PubMed
33.
Salmon M, Pilling D, Borthwick NJ, Viner N, Janossy G, Bacon PA, et al. The progressive differentiation of primed T cells is associated with an increasing susceptibility to apoptosis. Eur J immunol. 1994;24(4):892–9.PubMedCrossRef
34.
Dhein J, Walczak H, Bäumler C, Debatin K-M, Krammer PH. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature. 1995;373(6513):438.PubMedCrossRef
35.
Zheng L, Fisher G, Miller RE, Peschon J, Lynch DH, Lenardo MJ. Induction of apoptosis in mature T cells by tumour necrosis factor. Nature. 1995;377(6547):348.PubMedCrossRef
36.
Suda T, Okazaki T, Naito Y, Yokota T, Arai N, Ozaki S, et al. Expression of the Fas ligand in cells of T cell lineage. J Immunol. 1995;154(8):3806–13.PubMed
37.
Lynch DH, Ramsdell F, Alderson MR. Fas and FasL in the homeostatic regulation of immune responses. Immunol Today. 1995;16(12):569–74.PubMedCrossRef
38.
Hyde H, Borthwick NJ, Janossy G, Salmon M, Akbar AN. Upregulation of intracellular glutathione by fibroblast-derived factor (s): enhanced survival of activated T cells in the presence of low Bcl-2. Blood. 1997;89(7):2453–60.PubMed
39.
Ayroldi E, Zollo O, Cannarile L, D’Adamio F, Grohmann U, Delfino DV, et al. Interleukin-6 (IL-6) prevents activation-induced cell death: IL-2-independent inhibition of Fas/fasL expression and cell death. Blood. 1998;92(11):4212–9.PubMed
40.
Sandstrom PA, Mannie MD, Buttke TM. Inhibition of activation-induced death in T cell hybridomas by thiol antioxidants: oxidative stress as a mediator of apoptosis. J Leukoc Biol. 1994;55(2):221–6.PubMedCrossRef
41.
Williams MS, Henkart PA. Role of reactive oxygen intermediates in TCR-induced death of T cell blasts and hybridomas. J Immunol. 1996;157(6):2395–402.PubMed
42.
Marchetti P, Hirsch T, Zamzami N, Castedo M, Decaudin D, Susin SA, et al. Mitochondrial permeability transition triggers lymphocyte apoptosis. J Immunol. 1996;157(11):4830–6.PubMed
43.
Los M, Schenk H, Hexel K, Baeuerle PA, Dröge W, Schulze-Osthoff K. IL-2 gene expression and NF-kappa B activation through CD28 requires reactive oxygen production by 5-lipoxygenase. EMBO J. 1995;14(15):3731–40.PubMedPubMedCentralCrossRef
44.
Tatla S, Woodhead V, Foreman JC, Chain BM. The role of reactive oxygen species in triggering proliferation and IL-2 secretion in T cells. Free Radic Biol Med. 1999;26(1–2):14–24.PubMedCrossRef
45.
Hildeman DA, Mitchell T, Teague TK, Henson P, Day BJ, Kappler J, et al. Reactive oxygen species regulate activation-induced T cell apoptosis. Immunity. 1999;10(6):735–44.PubMedCrossRef
46.
Westermann J, Bode U. Distribution of activated T cells migrating through the body: a matter of life and death. Immunol Today. 1999;20(7):302–6.PubMedCrossRef
47.
Kessel RG. Basic medical histology: the biology of cells, tissues, and organs. Oxford: Oxford University Press; 1998.
48.
Rao RV, Ellerby H, Bredesen DE. Coupling endoplasmic reticulum stress to the cell death program. Cell Death Diff. 2004;11(4):372.CrossRef
49.
Chae H-J, Kim H-R, Xu C, Bailly-Maitre B, Krajewska M, Krajewski S, et al. BI-1 regulates an apoptosis pathway linked to endoplasmic reticulum stress. Mol Cell. 2004;15(3):355–66.PubMedCrossRef
50.
Ferri KF, Kroemer G. Organelle-specific initiation of cell death pathways. Nat Cell Biol. 2001;3(11):E255.PubMedCrossRef
51.
Breckenridge DG, Germain M, Mathai JP, Nguyen M, Shore GC. Regulation of apoptosis by endoplasmic reticulum pathways. Oncogene. 2003;22(53):8608.PubMedCrossRef
52.
Bakhshi J, Weinstein L, Poksay KS, Nishinaga B, Bredesen DE, Rao RV. Coupling endoplasmic reticulum stress to the cell death program in mouse melanoma cells: effect of curcumin. Apoptosis. 2008;13(7):904.PubMedPubMedCentralCrossRef
53.
54.
Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. Genes Dev. 1999;13(15):1899–911.PubMedCrossRef
55.
Dewson G, Kluck R. Bcl-2 family-regulated apoptosis in health and disease. Cell Health Cytoskelet. 2010;2(9):22.
56.
Quinlan DC, Davidson AG, Summers CL, Warden HE, Doshi HM. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res. 1992;52(17):4828–31.PubMed
57.
Denissenko MF, Pao A, Tang M-S, Pfeifer GP. Preferential formation of benzo [a] pyrene adducts at lung cancer mutational hotspots in P53. Science. 1996;274(5286):430–2.PubMedCrossRef
58.
Zhang E, Yin D, Sun M, Kong R, Liu X, You L, et al. P53-regulated long non-coding RNA TUG1 affects cell proliferation in human non-small cell lung cancer, partly through epigenetically regulating HOXB7 expression. Cell Death Dis. 2014;5(5):e1243.PubMedPubMedCentralCrossRef
59.
Wei Y, Fan T, Yu M. Inhibitor of apoptosis proteins and apoptosis. Acta Biochim Biophys Sin. 2008;40(4):278–88.PubMedCrossRef
60.
Rai K, Moore J, Wu J, Novick S, O’Brien S. Effect of the addition of oblimersen (Bcl-2 antisense) to fludarabine/cyclophosphamide for relapsed/refractory chronic lymphocytic leukemia (CLL) on survival in patients who achieve CR/nPR: five-year follow-up from a randomized phase III study. J Clin Oncol. 2008;26(15_suppl):7008.CrossRef
61.
62.
Russo M, Spagnuolo C, Volpe S, Tedesco I, Bilotto S, Russo GL. ABT-737 resistance in B-cells isolated from chronic lymphocytic leukemia patients and leukemia cell lines is overcome by the pleiotropic kinase inhibitor quercetin through Mcl-1 down-regulation. Biochem Pharmacol. 2013;85(7):927–36.PubMedCrossRef
63.
64.
65.
Luca M, Hunt B, Bucana C, Johnson J, Fidler I, Bar-Eli M. Direct correlation between MUC18 expression and metastatic potential of human melanoma cells. Melanoma Res. 1993;3(1):35–41.PubMedCrossRef
66.
Guezguez B, Vigneron P, Alais S, Jaffredo T, Gavard J, Mège R-M, et al. A dileucine motif targets MCAM-l cell adhesion molecule to the basolateral membrane in MDCK cells. FEBS Lett. 2006;580(15):3649–56.PubMedCrossRef
67.
Ouhtit A, Gaur RL, Elmageed ZYA, Fernando A, Thouta R, Trappey AK, et al. Towards understanding the mode of action of the multifaceted cell adhesion receptor CD146. Biochim Biophys Acta. 2009;1795(2):130–6.PubMed
68.
Anfosso F, Bardin N, Francès V, Vivier E, Camoin-Jau L, Sampol J, et al. Activation of human endothelial cells via S-Endo-1 antigen (CD146) stimulates the tyrosine phosphorylation of focal adhesion kinase p125FAK. J Biol Chem. 1998;273(41):26852–6.PubMedCrossRef
69.
Yan X, Lin Y, Yang D, Shen Y, Yuan M, Zhang Z, et al. A novel anti-CD146 monoclonal antibody, AA98, inhibits angiogenesis and tumor growth. Blood. 2003;102(1):184–91.PubMedCrossRef
70.
Zheng C, Qiu Y, Zeng Q, Zhang Y, Lu D, Yang D, et al. Endothelial CD146 is required for in vitro tumor-induced angiogenesis: the role of a disulfide bond in signaling and dimerization. Int J Biochem Cell Biol. 2009;41(11):2163–72.PubMedCrossRef
71.
Bu P, Gao L, Zhuang J, Feng J, Yang D, Yan X. Anti-CD146 monoclonal antibody AA98 inhibits angiogenesis via suppression of nuclear factor-κB activation. Mol Cancer Ther. 2006;5(11):2872–8.PubMedCrossRef
72.
Dranoff G. The therapeutic implications of intratumoral regulatory T cells. Clin Cancer Res. 2005;11(23):8226–9.PubMedCrossRef
73.
Flanagan K, Fitzgerald K, Baker J, Regnstrom K, Gardai S, Bard F, et al. Laminin-411 is a vascular ligand for MCAM and facilitates TH17 cell entry into the CNS. PLoS ONE. 2012;7(7):e40443.PubMedPubMedCentralCrossRef
74.
Ishikawa T, Wondimu Z, Oikawa Y, Ingerpuu S, Virtanen I, Patarroyo M. Monoclonal antibodies to human laminin α4 chain globular domain inhibit tumor cell adhesion and migration on laminins 411 and 421, and binding of α6β1 integrin and MCAM to α4-laminins. Matrix Biol. 2014;36:5–14.PubMedCrossRef
75.
Schneider-Hohendorf T, Rossaint J, Mohan H, Böning D, Breuer J, Kuhlmann T, et al. VLA-4 blockade promotes differential routes into human CNS involving PSGL-1 rolling of T cells and MCAM-adhesion of TH17 cells. J Exp Med. 2014;211(9):1833–46.PubMedPubMedCentralCrossRef
76.
Breuer J, Korpos E, Hannocks M-J, Schneider-Hohendorf T, Song J, Zondler L, et al. Blockade of MCAM/CD146 impedes CNS infiltration of T cells over the choroid plexus. J Neuroinflamm. 2018;15(1):236.CrossRef
77.
Jouve N, Despoix N, Espeli M, Gauthier L, Cypowyj S, Fallague K, et al. The involvement of CD146 and its novel ligand Galectin-1 in apoptotic regulation of endothelial cells. J Biol Chem. 2013;288(4):2571–9.PubMedCrossRef
78.
Jiang T, Zhuang J, Duan H, Luo Y, Zeng Q, Fan K, et al. CD146 is a coreceptor for VEGFR-2 in tumor angiogenesis. Blood. 2012;120(11):2330–9.PubMedCrossRef
79.
Ye Z, Zhang C, Tu T, Sun M, Liu D, Lu D, et al. Wnt5a uses CD146 as a receptor to regulate cell motility and convergent extension. Nature Commun. 2013;4:2803.CrossRef
80.
Solovey A, Gui L, Chang L, Enenstein J, Browne P, Hebbel RP. Identification and functional assessment of endothelial P1H12. J Lab Clin Med. 2001;138(5):322–31.PubMedCrossRef
81.
Li G, Kalabis J, Xu X, Meier F, Oka M, Bogenrieder T, et al. Reciprocal regulation of MelCAM and AKT in human melanoma. Oncogene. 2003;22(44):6891.PubMedCrossRef
82.
Pickl WF, Majdic O, Fischer GF, Petzelbauer P, Faé I, Waclavicek M, et al. MUC18/MCAM (CD146), an activation antigen of human T lymphocytes. J Immunol. 1997;158(5):2107–15.PubMed
83.
Şeftalioğlu A, Karakoç L. Expression of CD146 adhesion molecules (MUC18 or MCAM) in the thymic microenvironment. Acta Histochem. 2000;102(1):69–83.PubMedCrossRef
84.
Hadjinicolaou A, Wu L, Fang B, Watson P, Hall F, Busch R. Relationship of CD 146 expression to activation of circulating T cells: exploratory studies in healthy donors and patients with connective tissue diseases. Clin Exp Immunol. 2013;174(1):73–88.PubMedPubMedCentralCrossRef
85.
Schrage A, Loddenkemper C, Erben U, Lauer U, Hausdorf G, Jungblut PR, et al. Murine CD146 is widely expressed on endothelial cells and is recognized by the monoclonal antibody ME-9F1. Histochem Cell Biol. 2008;129(4):441–51.PubMedPubMedCentralCrossRef
86.
Fürstenberger G, Von Moos R, Senn H, Boneberg E. Real-time PCR of CD146 mRNA in peripheral blood enables the relative quantification of circulating endothelial cells and is an indicator of angiogenesis. Br J Cancer. 2005;93(7):793.PubMedPubMedCentralCrossRef
87.
Loges S, Clausen H, Reichelt U, Bubenheim M, Erbersdobler A, Schurr P, et al. Determination of microvessel density by quantitative real-time PCR in esophageal cancer: correlation with histologic methods, angiogenic growth factor expression, and lymph node metastasis. Clin Cancer Res. 2007;13(1):76–80.PubMedCrossRef
88.
Wu Z, Wu Z, Li J, Yang X, Wang Y, Yu Y, et al. MCAM is a novel metastasis marker and regulates spreading, apoptosis and invasion of ovarian cancer cells. Tumor Biol. 2012;33(5):1619–28.CrossRef
89.
Luo Y, Duan H, Qian Y, Feng L, Wu Z, Wang F, et al. Macrophagic CD146 promotes foam cell formation and retention during atherosclerosis. Cell Res. 2017;27(3):352.PubMedPubMedCentralCrossRef
90.
Corselli M, Crisan M, Murray IR, West CC, Scholes J, Codrea F, et al. Identification of perivascular mesenchymal stromal/stem cells by flow cytometry. Cytom Part A. 2013;83(8):714–20.CrossRef
91.
Tu T, Zhang C, Yan H, Luo Y, Kong R, Wen P, et al. CD146 acts as a novel receptor for netrin-1 in promoting angiogenesis and vascular development. Cell Res. 2015;25(3):275.PubMedPubMedCentralCrossRef
92.
93.
Wu G-J, Dickerson EB. Frequent and increased expression of human METCAM/MUC18 in cancer tissues and metastatic lesions is associated with the clinical progression of human ovarian carcinoma. Taiwanese J Obs Gynecol. 2014;53(4):509–17.CrossRef
94.
95.
Zeng P, Li H, Lu P-H, Zhou L-N, Tang M, Liu C-Y, et al. Prognostic value of CD146 in solid tumor: a systematic review and meta-analysis. Sci Rep. 2017;7(1):4223.PubMedPubMedCentralCrossRef
96.
Wu G-J. Resolving the controversial role of METCAM/MUC18 in the progression of human breast cancer. Breast, cervical and prostate cancer. Brisbane: Hard Cover; iConcept Press Ltd; 2014. p. 87–100.
97.
Wu G-J. Dual Role of METCAM/MUC18 expression in the progression of cancer cells. In: Gene expression and regulation in mammalian cells-transcription from general aspects. IntechOpen; 2018.
98.
Wang W, Yang Z-L, Liu J-Q, Jiang S, Miao X-Y. Identification of CD146 expression, angiogenesis, and lymphangiogenesis as progression, metastasis, and poor-prognosis related markers for gallbladder adenocarcinoma. Tumor Biol. 2012;33(1):173–82.CrossRef
99.
Wu G-J, Wu M-WH, Wang S-W, Liu Z, Qu P, Peng Q, et al. Isolation and characterization of the major form of human MUC18 cDNA gene and correlation of MUC18 over-expression in prostate cancer cell lines and tissues with malignant progression. Gene. 2001;279(1):17–31.PubMedCrossRef
100.
Watson-Hurst K, Becker D. The role of N-Cadherin, MCAM, and β3 integrin in melanoma progression, proliferation, migration and invasion. Cancer Biol Therapy. 2006;5(10):1375–82.CrossRef
101.
Garcia S, Dalès J-P, Charafe-Jauffret E, Carpentier-Meunier S, Andrac-Meyer L, Jacquemier J, et al. Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype. Hum Pathol. 2007;38(6):830–41.PubMedCrossRef
102.
Zhang X, Wang Z, Kang Y, Li X, Ma X, Ma L. MCAM expression is associated with poor prognosis in non-small cell lung cancer. Clin Transl Oncol. 2014;16(2):178–83.PubMedCrossRef
103.
Oka S, Uramoto H, Chikaishi Y, Tanaka F. The expression of CD146 predicts a poor overall survival in patients with adenocarcinoma of the lung. Anticancer Res. 2012;32(3):861–4.PubMed
104.
Alama A, Truini A, Coco S, Genova C, Grossi F. Prognostic and predictive relevance of circulating tumor cells in patients with non-small-cell lung cancer. Drug Dis Today. 2014;10(19):1671–6.CrossRef
105.
Jiang G, Zhang L, Zhu Q, Bai D, Zhang C, Wang X. CD146 promotes metastasis and predicts poor prognosis of hepatocellular carcinoma. J Exp Clin Cancer Res. 2016;35(1):38.PubMedPubMedCentralCrossRef
106.
Hernandez R, Sun H, England CG, Valdovinos HF, Ehlerding EB, Barnhart TE, et al. CD146-targeted immunoPET and NIRF imaging of hepatocellular carcinoma with a dual-labeled monoclonal antibody. Theranostics. 2016;6(11):1918.PubMedPubMedCentralCrossRef
107.
Aldovini D, Demichelis F, Doglioni C, Di Vizio D, Galligioni E, Brugnara S, et al. M-CAM expression as marker of poor prognosis in epithelial ovarian cancer. Int J Cancer. 2006;119(8):1920–6.PubMedCrossRef
108.
Zeng Q, Li W, Lu D, Wu Z, Duan H, Luo Y, et al. CD146, an epithelial-mesenchymal transition inducer, is associated with triple-negative breast cancer. Proc Natl Acad Sci. 2012;109(4):1127–32.PubMedCrossRef
109.
Zabouo G, Imbert A-M, Jacquemier J, Finetti P, Moreau T, Esterni B, et al. CD146 expression is associated with a poor prognosis in human breast tumors and with enhanced motility in breast cancer cell lines. Breast Cancer Res. 2009;11(1):R1.PubMedPubMedCentralCrossRef
110.
111.
Li Y, Yu J-M, Zhan X-M, Liu L-L, Jin N, Zhang Y-X. Correlation of CD146 expression and clinicopathological characteristics in esophageal squamous cell carcinoma. Oncol Lett. 2014;8(2):859–63.PubMedPubMedCentralCrossRef
112.
Tian B, Zhang Y, Li N. CD146 protein as a marker to predict postoperative liver metastasis in colorectal cancer. Cancer Biotherapy Radiopharm. 2013;28(6):466–70.CrossRef
113.
Liu W-F, Ji S-R, Sun J-J, Zhang Y, Liu Z-Y, Liang A-B, et al. CD146 expression correlates with epithelial-mesenchymal transition markers and a poor prognosis in gastric cancer. Int J Mol Sci. 2012;13(5):6399–406.PubMedPubMedCentralCrossRef
114.
Feng G, Fang F, Liu C, Zhang F, Huang H, Pu C. CD146 gene expression in clear cell renal cell carcinoma: a potential marker for prediction of early recurrence after nephrectomy. Int Urol Nephrol. 2012;44(6):1663–9.PubMedCrossRef
115.
Sers C, Riethmüller G, Johnson JP. MUC18, a melanoma-progression associated molecule, and its potential role in tumor vascularization and hematogenous spread. Cancer Res. 1994;54(21):5689–94.PubMed
116.
Filshie R, Zannettino A, Makrynikola V, Gronthos S, Henniker A, Bendall L, et al. MUC18, a member of the immunoglobulin superfamily, is expressed on bone marrow fibroblasts and a subset of hematological malignancies. Leu. 1998;12(3):414.
117.
Shih I-M, Wang T-L, Westra WH. Diagnostic and biological implications of mel-CAM expression in mesenchymal neoplasms. Clin Cancer Res. 1996;2(3):569–75.PubMed
118.
Pires FR, Shih I-M, da Cruz Perez DE, De Almeida OP, Kowalski LP. Mel-CAM (CD146) expression in parotid mucoepidermoid carcinoma. Oral Oncol. 2003;39(3):277–81.PubMedCrossRef
119.
Li Q, Yu Y, Bischoff J, Mulliken JB, Olsen BR. Differential expression of CD146 in tissues and endothelial cells derived from infantile haemangioma and normal human skin. J Pathol. 2003;201(2):296–302.PubMedCrossRef
120.
Chen W, Zhang H, Jiang Y, Li J, Liu B, Sun M. Inhibition of CD146 gene expression via RNA interference reduces in vitro perineural invasion on ACC-M cell. J Oral Pathol Med. 2009;38(2):198–205.PubMedCrossRef
121.
Sato A, Torii I, Okamura Y, Yamamoto T, Nishigami T, Kataoka TR, et al. Immunocytochemistry of CD146 is useful to discriminate between malignant pleural mesothelioma and reactive mesothelium. Mod Pathol. 2010;23(11):1458.PubMedCrossRef
122.
Wu GJ, Varma VA, Wu MWH, Wang SW, Qu P, Yang H, et al. Expression of a human cell adhesion molecule, MUC18, in prostate cancer cell lines and tissues. Prostate. 2001;48(4):305–15.PubMedCrossRef
123.
Zhang H, Zhang J, Wang Z, Lu D, Feng J, Yang D, et al. CD146 is a potential marker for the diagnosis of malignancy in cervical and endometrial cancer. Oncol Lett. 2013;5(4):1189–94.PubMedPubMedCentralCrossRef
Metadata
Title
CD146 T cells in lung cancer: its function, detection, and clinical implications as a biomarker and therapeutic target
Authors
Ayobami Matthew Olajuyin
Adefunke Kafayat Olajuyin
Ziqi Wang
Xingru Zhao
Xiaoju Zhang
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2019
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-019-0969-9

Other articles of this Issue 1/2019

Cancer Cell International 1/2019 Go to the issue

Primary research

Interfering cellular lactate homeostasis overcomes Taxol resistance of breast cancer cells through the microRNA-124-mediated lactate transporter (MCT1) inhibition

Primary research

Large tumor suppressor kinase 2 overexpression attenuates 5-FU-resistance in colorectal cancer via activating the JNK-MIEF1-mitochondrial division pathway

Primary research

Differential secretome of pancreatic cancer cells in serum-containing conditioned medium reveals CCT8 as a new biomarker of pancreatic cancer invasion and metastasis

Primary research

Circadian protein BMAL1 promotes breast cancer cell invasion and metastasis by up-regulating matrix metalloproteinase9 expression

Primary research

TP53 mutant cell lines selected for resistance to MDM2 inhibitors retain growth inhibition by MAPK pathway inhibitors but a reduced apoptotic response

Primary research

Leucine-rich repeat and sterile alpha motif containing 1 promotes the oncogenic growth of human hepatocellular carcinoma cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits